TFE3 fusion proteins are the oncogenic drivers of translocation renal cell carcinoma but their mechanism of action remains ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 ...

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology and autoimmune diseases, will present updated clinical and ...

A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or ...

Aura Biosciences (AURA) announced data from a completed Phase 1 window of opportunity trial of bel-sar in patients with NMIBC. These data were ...

PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...

Iron-dependent ferroptosis, a non-apoptotic cell death mechanism, is gaining attention for its role in immune suppression.

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

A DNA nanomachine selectively targets skin cancer by detecting microRNA-7, activating phototherapy and releasing chemotherapy ...

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...